Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

By Samir S. Taneja. Journal of Urology, 2013

1,844 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1f58d47442da974974faa8d8376431c21d62ee57

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Celestia S. Higano
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. Thomas Wiegel
7. M. Hallek

Citations in the corpus

• Genetics and biology of prostate cancer (2018, background): “Abiraterone, a CYP17A1 inhibitor that blocks androgen production, also improves survival of patients with advanced prostate cancer with or without prior chemotherapy (de Bono et al. 2011; Ryan et al. 2013; Fizazi et al. 2017; James et al. 2017).”
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. (2018, neutral): “796 0 101 (50) 15 (56) 69 (52) 19 (45) 1 85 (42) 9 (33) 53 (40) 21 (50) 2 7 (3) 2 (7) 5 (4) 1 (2) Unknown 9 (4) 1 (4) 6 (5) 1 (2) Prior treatment First-generation antiandrogen (bicalutamide, flutamide, nilutamide) 182 (90) 25 (93) 118 (89) 38 (90) .”
• PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer (2016, background): “Sprenger C, Uo T, Plymate S (2015) Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: A coming of age for AR splice variants? Ann Oncol 26(9):1805–1807.”
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016, background): “PCWG3 retains the PCWG2 criteria for PSA progression.(5,6,10,11) For nmCRPC, PCWG3 advises recording PSA doubling times (PSADTs) and focusing drug development efforts on patients with shorter times who have the greatest risk of developing detectable metastatic disease or symptoms, and dying of their”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, methodology): “Patients were randomised to abiraterone acetate or placebo, both combined with prednisone [74].”